Page last updated: 2024-11-03

probucol and Hyperlipemia

probucol has been researched along with Hyperlipemia in 123 studies

Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.

Research Excerpts

ExcerptRelevanceReference
"A multicenter study was undertaken to compare the effects of lovastatin (given in 4 different dosage regimens) and probucol in patients with severe primary hypercholesterolemia."9.06A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV. ( , 1990)
"In a prospective, uncontrolled multicenter study, we have evaluated the effects of probucol on hyperlipidemia, proteinuria, and glomerular filtration rate (GFR) in hyperlipidemic children with persistent nephrotic syndrome."7.70Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study. ( Fiehn, W; Kohl, B; Michalk, D; Minor, T; Müller-Wiefel, DE; Querfeld, U; Schärer, K, 1999)
"Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats."7.68The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991)
"We have evaluated the effect of the antihyperlipidemic agent probucol on hyperlipidemia in patients with nephrotic syndrome."7.67Effect of probucol on hyperlipidemia in patients with nephrotic syndrome. ( Asaka, M; Fujita, M; Iida, H; Izumino, K; Nishino, A; Sasayama, S, 1987)
"High-fat pancreatitis and hyperlipidemia refer to disorders of blood lipid metabolism caused by abnormally elevated blood lipids, and are risk factors for high-risk diseases such as atherosclerosis, coronary heart disease, and cerebral infarction."5.62Study on the Mechanism of Probucol Nanosuspension on Hyperlipidemic Pancreatitis and Regulation of Blood Lipid Function. ( Jiang, X; Wang, X; Wu, Z, 2021)
"Hypercholesterolemic patients with coronary artery disease were randomized to three groups and received study drugs for 3 years: the control with statin alone; the probucol group with statin and probucol; and the combo group with statin, probucol, and cilostazol."5.41Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study. ( Ge, J; Kang, HJ; Kim, CH; Kim, MH; Kim, SH; Oh, BH; Park, JE; Sung, J, 2021)
"Nephrotic syndrome accompanies hyperlipidemia for which HMG-CoA reductase inhibitors are mainly used."5.31[Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome]. ( Aoki, M; Futami, T; Inui, K; Muso, E; Ono, T; Osawa, R; Wakasugi, H; Yoshimoto, M, 2001)
"Probucol is shown to be a better accelerator for lipid clearance in triton hyperlipidemia than clofibrate."5.27Effect of probucol on triton induced hyperlipidemias in CFY rats. ( Krishnamurthy, A; Shridhar, DR; Thapar, GS, 1985)
"A multicenter study was undertaken to compare the effects of lovastatin (given in 4 different dosage regimens) and probucol in patients with severe primary hypercholesterolemia."5.06A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV. ( , 1990)
"We describe that high-dose methylprednisolone (20 mg/kg) can induce multifocal osteonecrosis (ON) in conjunction with thrombocytopenia, hypofibrinogenemia, and hyperlipemia."4.84[Animal models for steroid-induced osteonecrosis]. ( Iwamoto, Y; Miyanishi, K; Motomura, G; Nishida, K; Sueishi, K; Yamamoto, T, 2007)
" In this study, serum lipid profiles and heart protective effects were evaluated in high fat diet (HFD) induced hyperlipidemia in aging rats treated with APPH (15, 45 and 75 mg/kg/day) and probucol (500 mg/kg/day)."3.81The Heart Protection Effect of Alcalase Potato Protein Hydrolysate Is through IGF1R-PI3K-Akt Compensatory Reactivation in Aging Rats on High Fat Diets. ( Chang, CH; Chiang, WD; Hu, WS; Huang, CY; Lin, WT; Pai, P; Ting, WJ; Yeh, YL, 2015)
"In a prospective, uncontrolled multicenter study, we have evaluated the effects of probucol on hyperlipidemia, proteinuria, and glomerular filtration rate (GFR) in hyperlipidemic children with persistent nephrotic syndrome."3.70Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study. ( Fiehn, W; Kohl, B; Michalk, D; Minor, T; Müller-Wiefel, DE; Querfeld, U; Schärer, K, 1999)
"Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats."3.68The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991)
"We have evaluated the effect of the antihyperlipidemic agent probucol on hyperlipidemia in patients with nephrotic syndrome."3.67Effect of probucol on hyperlipidemia in patients with nephrotic syndrome. ( Asaka, M; Fujita, M; Iida, H; Izumino, K; Nishino, A; Sasayama, S, 1987)
"Probucol is a potent antioxidant and reduces tendon xanthomas in familial hypercholesterolemia patients despite reduction of high-density lipoprotein (HDL)-cholesterol (HDL-C)."3.01Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE). ( Arai, H; Bujo, H; Doi, Y; Fukushima, M; Ishibashi, T; Kita, T; Masuda, D; Matsuzaki, M; Matsuzawa, Y; Nakagawa, S; Ohama, T; Saito, Y; Tanabe, K; Yamashiro, K; Yamashita, S; Yanagi, K, 2021)
"Probucol has a major, and vitamin E a minor, effect on LDL resistance to oxidation but neither compound appears to alter forearm vascular responses in vivo."2.67The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans. ( Brennan, GM; Bruce, I; Johnston, GD; McDowell, IF; McEneny, J; McVeigh, GE; Nicholls, DP; Trimble, ER; Young, IS, 1994)
"7%) on probucol reported mild to moderately severe side-effects, mainly gastro-intestinal, but in no case was treatment interrupted, although benzafibrate dosage was temporarily reduced."2.66Comparative study of bezafibrate and probucol in hyperlipidaemia. ( González, G; Páez Moreno, JP, 1989)
" In 32 patients with Type II HL and 12 with Type IIB HL, statistically significant reduction in mean serum cholesterol levels occurred within two weeks and persisted throughout two years of therapy at constant dosage (500 mg."2.64Effect of probucol in hyperlipidemic patients during two years of administration. ( Parsons, WB, 1978)
"When probucol was added to the diet of the responders, their plasma cholesterol level was lowered a further 13%."2.64Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia. ( Davignon, J; DuBreuil-Quidoz, S; Huang, YS; LeLorier, J; Lussier-Cacan, S, 1977)
"Several forms of dyslipidemia are associated with premature coronary artery disease (CAD) and other vascular disease."2.39Hyperlipidemia: perspectives in diagnosis and treatment. ( Gotto, AM; Yeshurun, D, 1995)
"Hyperlipidemia should be managed systematically using information about the association between increased lipid concentrations and CAD, patient risk factors, and limitations of both diet and drug therapy."2.37Contemporary recommendations for evaluating and treating hyperlipidemia. ( Perry, RS, 1986)
"High-fat pancreatitis and hyperlipidemia refer to disorders of blood lipid metabolism caused by abnormally elevated blood lipids, and are risk factors for high-risk diseases such as atherosclerosis, coronary heart disease, and cerebral infarction."1.62Study on the Mechanism of Probucol Nanosuspension on Hyperlipidemic Pancreatitis and Regulation of Blood Lipid Function. ( Jiang, X; Wang, X; Wu, Z, 2021)
"Atherosclerosis is a multifactorial disease with several mechanisms participating in its manifestation."1.37Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents. ( Katselou, MG; Kourounakis, AP; Matralis, AN; Nikitakis, A, 2011)
"The probucol and DR groups were fed the same diet as the control group but with the addition of 100 mg probucol/kg chow and 200 mg DR/kg chow, respectively."1.33Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome. ( Chang, WC; Tseng, YH; Wu, CH; Wu, KY; Yu, YM, 2005)
"Ellagic acid is a phenolic compound present in fruits and nuts, and has been found to have antioxidative property."1.33Reduction of oxidative stress and apoptosis in hyperlipidemic rabbits by ellagic acid. ( Chang, WC; Chiang, SY; Wu, CH; Yu, YM, 2005)
"Probucol is a lipid-lowering agent with an antioxidant effect; however, its influence on the liver remains unclear."1.31Effects of probucol in hyperlipidemic rabbit liver: a preliminary ultrastructural study. ( Aktuna Keskil, Z; Aşan, E; Korkusuz, P; Ugur, Y; Uluoglu, C, 2002)
"Nephrotic syndrome accompanies hyperlipidemia for which HMG-CoA reductase inhibitors are mainly used."1.31[Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome]. ( Aoki, M; Futami, T; Inui, K; Muso, E; Ono, T; Osawa, R; Wakasugi, H; Yoshimoto, M, 2001)
"Quercetin treated animals did not show increased oxidation of LDL (and VLDL in rabbits) and cholesterol levels were not decreased."1.30Probucol selectively increases oxidation of atherogenic lipoproteins in cholesterol-fed mice and in Watanabe heritable hyperlipidemic rabbits. ( Lauridsen, ST; Mortensen, A, 1999)
"This appears to be due both to reduced coronary atherosclerosis and to a different, more stable type of atherosclerotic disease in this animal model."1.30Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet. ( Bräsen, JH; Harsch, M; Niendorf, A, 1998)
" Thus, long-term administration appears to suppress the progression of atherosclerotic vascular disease in this animal model."1.30Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits. ( Aoki, K; Hori, M; Hoshida, S; Igarashi, J; Kuzuya, T; Yamashita, N, 1997)
"A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction."1.30Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997)
"Probucol was without effect on this index of in vivo LDL oxidation."1.29Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. ( Demacker, PN; Kleinveld, HA; Stalenhoef, AF, 1994)
"Probucol treatment significantly reduced the lipid concentration in all major lipoproteins, significantly reduced proteinuria and increased plasma albumin concentration."1.28Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis. ( Hirano, T; Morohoshi, T, 1992)
"Probucol treatment resulted in a change not only in the size but also the composition of lesions."1.28Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit--long-term antiatherogenic effect and effects on established plaques. ( Cho, M; Kita, T; Matsuzawa, Y; Nagano, Y; Nakamura, T; Ueda, Y, 1992)
" In addition to survey in 6,002 patients, the effect on regression of xanthomas and safety in long-term administration of over one year was investigated in 44 and 142 patients, respectively."1.28Post-marketing surveillance of probucol (Sinlestal) in Japan. ( Kosasayama, A; Okada, S; Yoshida, M, 1992)
"1."1.28The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits. ( Daugherty, A; Schonfeld, G; Zweifel, BS, 1991)
"Probucol has been used as a lipid-lowering agent for over 10 years."1.28Antiatherosclerotic effect of probucol in WHHL rabbits: are there plasma parameters to evaluate this effect? ( Beisiegel, U; Finckh, B; Niendorf, A; Rath, M, 1991)
"Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia."1.27Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986)
"Oral carnitine has been reported to have a lipid-lowering effect with concomitant elevation of high density lipoprotein cholesterol (HDL-C) levels in normo- and hyperlipidemic individuals."1.27Plasma carnitine and lipid-lowering drugs. ( Davignon, J; Nestruck, AC; Pande, SV, 1985)
"Probucol is shown to be a better accelerator for lipid clearance in triton hyperlipidemia than clofibrate."1.27Effect of probucol on triton induced hyperlipidemias in CFY rats. ( Krishnamurthy, A; Shridhar, DR; Thapar, GS, 1985)
" Adverse side effects ranging from mere annoyances to uncommon serious consequences may be associated with dietary modification, recreational physical exercise, and drug intervention."1.27Adverse effects of the treatment for hyperlipidemia. ( Malinow, MR, 1986)

Research

Studies (123)

TimeframeStudies, this research(%)All Research%
pre-199043 (34.96)18.7374
1990's46 (37.40)18.2507
2000's24 (19.51)29.6817
2010's6 (4.88)24.3611
2020's4 (3.25)2.80

Authors

AuthorsStudies
Matralis, AN2
Katselou, MG1
Nikitakis, A1
Kourounakis, AP2
Ladopoulou, E1
Yamashita, S2
Arai, H1
Bujo, H1
Masuda, D2
Ohama, T1
Ishibashi, T1
Yanagi, K1
Doi, Y1
Nakagawa, S2
Yamashiro, K1
Tanabe, K1
Kita, T4
Matsuzaki, M1
Saito, Y2
Fukushima, M1
Matsuzawa, Y3
Kang, HJ1
Kim, MH1
Sung, J1
Kim, SH1
Kim, CH1
Park, JE1
Ge, J1
Oh, BH1
Wu, Z1
Wang, X1
Jiang, X1
Ma, Q1
Han, Y1
Chen, C1
Cao, Y1
Wang, S1
Shen, W1
Zhang, H1
Li, Y1
van Dongen, MA1
He, B1
Yu, M1
Xu, L1
Banaszak Holl, MM1
Liu, G1
Zhang, Q1
Qi, R1
Hu, WS1
Ting, WJ1
Chiang, WD1
Pai, P1
Yeh, YL1
Chang, CH1
Lin, WT1
Huang, CY1
Jung, YS1
Park, JH1
Kim, H1
Kim, SY1
Hwang, JY1
Hong, KW1
Bae, SS1
Choi, BT1
Lee, SW1
Shin, HK1
Yasuda, G1
Ando, D1
Hirawa, N1
Umemura, S1
Korkusuz, P1
Ugur, Y1
Aşan, E1
Aktuna Keskil, Z1
Uluoglu, C1
Horiuchi, K1
Takatori, A1
Inenaga, T1
Ohta, E1
Yamanouchi, J1
Kawamura, S1
Ishii, Y1
Kyuwa, S1
Yoshikawa, Y2
Asberg, A1
Gotto, AM3
Nomura, S1
Takahashi, N1
Inami, N1
Kajiura, T1
Yamada, K1
Nakamori, H1
Tsuda, N1
Wenke, K1
Ohtani, K1
Egashira, K1
Finné Nielsen, IL1
Elbøl Rasmussen, S1
Mortensen, A2
Ravn-Haren, G1
Ma, HP1
Knuthsen, P1
Hansen, BF1
McPhail, D1
Freese, R1
Breinholt, V1
Frandsen, H1
Dragsted, LO1
Chang, WC2
Yu, YM2
Wu, CH2
Tseng, YH1
Wu, KY1
Chiang, SY1
Tanimoto, T1
Yamamoto, T1
Miyanishi, K1
Motomura, G1
Nishida, K1
Iwamoto, Y1
Sueishi, K1
Ayaori, M1
Ogura, M1
Kusuhara, M1
Fukumoto, Y1
Shimokawa, H1
Nash, DT2
Bertolami, MC1
Bertolami, V1
Hunninghake, DB1
Nestel, PJ1
Ng, AS1
Johan, A1
Quek, SS1
Tan, IK1
Melico-Sylvestre, AA1
Jacotot, B1
Buxtorf, JC1
Beaumont, V1
Beaumont, JL1
Giannini, SD3
Forti, N3
Ziliotto, EE1
Samuel, P1
Tillement, JP1
Albengres, E1
Choisy, H1
Millart, H1
Yeshurun, D1
Yamasaki, K1
Fiorini, F1
Patrone, E1
Castelluccio, A1
McDowell, IF1
Brennan, GM1
McEneny, J1
Young, IS1
Nicholls, DP2
McVeigh, GE1
Bruce, I1
Trimble, ER1
Johnston, GD1
Kuo, PT1
Kleinveld, HA2
Demacker, PN2
Stalenhoef, AF2
Malloy, MJ1
Kane, JP1
Lankin, VZ2
Revenko, VM2
Lupanov, VP3
Tikhaze, AK2
Liakishev, AA1
Kukharchuk, VV1
Hijmans, AG1
Shinomiya, M1
Shirai, K1
Yoshida, S1
Betteridge, DJ1
Dodson, PM1
Durrington, PN1
Hughes, EA1
Laker, MF1
Rees, JA1
Seymour, CA1
Thompson, GR1
Winder, AF1
Ozawa, K1
Mann, WA1
Windler, E1
Beil, FU1
Greten, H1
Bravo, E1
Ortu, G1
Rivabene, R1
Santini, MT1
Cantafora, A1
Kesten, S1
Mayne, L1
Scavuzzo, M1
Maurer, J1
Hoshida, S1
Yamashita, N1
Igarashi, J1
Aoki, K1
Kuzuya, T1
Hori, M1
Mikhin, VP1
Itoh, H1
Komori, K1
Okazaki, J1
Mawatari, K1
Kawasaki, K1
Kuma, S1
Eguchi, D1
Sugimachi, K1
Oshima, R1
Ikeda, T1
Watanabe, K1
Itakura, H2
Sugiyama, N1
Davignon, J4
Bräsen, JH1
Harsch, M1
Niendorf, A2
Leng, GC1
Price, JF1
Jepson, RG1
Lauridsen, ST1
Querfeld, U1
Kohl, B1
Fiehn, W1
Minor, T1
Michalk, D1
Schärer, K1
Müller-Wiefel, DE1
Witting, P1
Pettersson, K1
Ostlund-Lindqvist, AM1
Westerlund, C1
Wâgberg, M1
Stocker, R1
Allott, CP1
Barry, CD1
Bramley, J1
John, NW1
Mellor, PM1
Thomson, DS1
Reilly, CF1
Shi, A1
Yoshinari, M1
Iino, K1
Wakisaka, M1
Iwase, M1
Fujishima, M1
El-Swefy, S1
Schaefer, EJ1
Seman, LJ1
van Dongen, D1
Sevanian, A1
Smith, DE1
Ordovas, JM1
El-Sweidy, M1
Meydani, M1
Batra, S1
Srivastava, S1
Singh, K1
Chander, R1
Khanna, AK1
Bhaduri, AP1
Anikin, VV1
Savin, VV1
Razygraev, RA1
Titov, VN1
Zaĭtseva, TM1
Djahansouzi, S1
Braesen, JH1
Koenig, K1
Beisiegel, U2
Kontush, A1
Yagyu, H1
Ogaki, S1
Matsushima, T1
Hirano, T4
Yoshino, G1
Kimura, Y1
Uchiyama, S1
Wakasugi, H1
Yoshimoto, M1
Aoki, M1
Osawa, R1
Futami, T1
Ono, T1
Muso, E1
Inui, K1
Murphy, BF1
LeLorier, J1
DuBreuil-Quidoz, S1
Lussier-Cacan, S1
Huang, YS1
Heel, RC1
Brogden, RN1
Speight, TM1
Avery, GS1
Parsons, WB1
Diament, J1
Fleischmajer, R1
Miettinen, TA2
Paterson, JR1
Rumley, AG1
Oldroyd, KG1
Tait, GW1
Smellie, WS1
Packard, CJ1
Shepherd, J1
Lorimer, AR1
Grundy, SM3
Morohoshi, T1
Nagano, Y3
Nakamura, T1
Cho, M1
Ueda, Y1
Kosasayama, A1
Yoshida, M1
Okada, S1
Mimura, K1
Yukawa, S1
Avogaro, P1
Cazzolato, G1
Bittolo-Bon, G1
Mamo, JC2
Nagano, S1
Sugisaki, T2
Daugherty, A1
Zweifel, BS1
Schonfeld, G1
Finckh, B1
Rath, M1
D'Amico, G1
Gentile, MG1
Kesäniemi, YA1
Noma, A1
Maeda, S1
Okuno, M1
Abe, A1
Muto, Y1
Ohnami, K1
Páez Moreno, JP1
González, G1
Mori, Y1
Wada, H1
Deguchi, K1
Shirakawa, S1
Huttunen, JK1
Naukkarinen, V1
Strandberg, T1
Vanhanen, H1
Dereviacki, BE1
Naito, HK1
Yokode, M1
Ishii, K1
Kume, N1
Narumiya, S1
Kawai, C1
Steinberg, D2
Parthasarathy, S1
Carew, TE2
Tikkanen, MJ1
Nikkilä, EA1
Schwenke, DC1
Perry, RS1
Malinow, MR1
Jones, PH1
Scott, LW1
LaRosa, JC1
Iida, H1
Izumino, K1
Asaka, M1
Fujita, M1
Nishino, A1
Sasayama, S1
Graham, I1
Ronan, G1
Comerford, D1
Hickey, N1
Daly, L1
Mulcahy, R1
Feder, D1
Langer, AL1
Alexandrino, E1
Medeiros, S1
Lotto, M1
Valente, O1
Nestruck, AC1
Pande, SV1
Krishnamurthy, A1
Thapar, GS1
Shridhar, DR1
de Meglio, P1
Ravenna, F1
Manzardo, S1
Gentili, P1
Riva, M1
Sirtori, C1
Fumagalli, R1
Paoletti, R1
Brown, HB1
De Wolfe, VG1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome[NCT00988364]Phase 430 participants (Actual)Interventional2007-03-31Completed
Classic Ketogenic Diet and Modified: Evaluation of the Therapeutic Potential and Impact on the Oxidative Profile, Lipidomic, Inflammatory and Size of Lipoproteins in Children and Adolescents With Refractory Epilepsy[NCT02644239]60 participants (Anticipated)Interventional2012-06-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

L5 Concentration After Treatment of Ezetimibe, Simvastatin, or Vytorin in Metabolic Syndrome Patients

Patient's blood samples were collected at the corresponding time point for L5 purification. L5 quantification and characterization were investigated with chemical analysis, proteomics and in-vitro cell signaling analysis. Final data analysis will determine total L5 concentration (mg/dL). (NCT00988364)
Timeframe: 3 months

Interventionmg/dL (Mean)
Ezetimibe30.17
Simvastatin19.19
Vytorin14.17
Placebo15.15

L5 Concentration in Metabolic Syndrome Patients

Patient's blood samples were collected before treatment. L5 were purified by ultracentrifugation then FPLC. Quantification analysis will indicate the L5 concentration (mg/dL) per group. (NCT00988364)
Timeframe: 0 months, at the start

Interventionmg/dL (Mean)
Ezetimibe35.97
Simvastatin17.8233
Vytorin29.736
Placebo23.1

Reviews

30 reviews available for probucol and Hyperlipemia

ArticleYear
Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.
    Drugs, 2003, Volume: 63, Issue:4

    Topics: Acids, Acyclic; Area Under Curve; Bile Acids and Salts; Clinical Trials as Topic; Cyclosporine; Drug

2003
Antioxidants, statins, and atherosclerosis.
    Journal of the American College of Cardiology, 2003, Apr-02, Volume: 41, Issue:7

    Topics: Animals; Antioxidants; Ascorbic Acid; beta Carotene; Clinical Trials as Topic; Coronary Artery Disea

2003
Management of hyperlipidaemia associated with heart transplantation.
    Drugs, 2004, Volume: 64, Issue:10

    Topics: Anticholesteremic Agents; Carrier Proteins; Cholesterol, LDL; Fatty Acids, Omega-3; Heart Transplant

2004
[NO and atherosclerosis].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 9

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Arginine; Arteriosclerosis; Endothe

2004
[Research and developmental strategy of anti-dyslipidemic agents].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2007, Volume: 129, Issue:4

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Apolipoprotein A-I; Carrier Proteins; Chole

2007
[Animal models for steroid-induced osteonecrosis].
    Clinical calcium, 2007, Volume: 17, Issue:6

    Topics: Animals; Anticholesteremic Agents; Anticoagulants; Disease Models, Animal; Dose-Response Relationshi

2007
[Probucol].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Jul-28, Volume: 65 Suppl 7

    Topics: Anticholesteremic Agents; Humans; Hyperlipidemias; Probucol

2007
[Adverse effects of lipid-lowering medications].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Oct-28, Volume: 65 Suppl 8

    Topics: Anticholesteremic Agents; Arteriosclerosis; Clofibric Acid; Contraindications; Humans; Hydroxymethyl

2007
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
    Circulation, 1984, Volume: 69, Issue:5

    Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl

1984
Hyperlipidemia: perspectives in diagnosis and treatment.
    Southern medical journal, 1995, Volume: 88, Issue:4

    Topics: Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Diet, Fat-Re

1995
Dyslipidemia and coronary artery disease.
    Clinical cardiology, 1994, Volume: 17, Issue:10

    Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; H

1994
Medical management of hyperlipidemic states.
    Advances in internal medicine, 1994, Volume: 39

    Topics: Coronary Disease; Diet Therapy; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Pancrea

1994
Trials of the effects of drugs and hormones on lipids and lipoproteins.
    Current opinion in lipidology, 1995, Volume: 6, Issue:6

    Topics: Clinical Trials as Topic; Estrogen Replacement Therapy; Female; Hormones; Human Growth Hormone; Huma

1995
Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects.
    The American journal of cardiology, 1998, Apr-23, Volume: 81, Issue:8A

    Topics: Animals; Clofibrate; Drug Evaluation; Drug Evaluation, Preclinical; Drugs, Investigational; Humans;

1998
[Discrimination between the effects of hypolipidemic and antiatherogenic drugs: probucol pharmacokinetics (review of the literature)].
    Klinicheskaia laboratornaia diagnostika, 2000, Issue:8

    Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Animals; Anticholesteremic Agents; Arterioscle

2000
[Probucol].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3

    Topics: Angioplasty, Balloon, Coronary; Animals; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; C

2001
[Nicotinic acid and the derivative].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3

    Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Hum

2001
[Treatments for dyslipidemia associated with kidney disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3

    Topics: Anion Exchange Resins; Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibit

2001
[Hyperlipidemia and cerebrovascular disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 2

    Topics: Anticholesteremic Agents; Apolipoproteins; Cerebral Infarction; Cerebrovascular Disorders; Cholester

2001
Diet and drug synergism in treatment of hypercholesterolemia.
    Nutrition reviews, 1978, Volume: 36, Issue:1

    Topics: Adult; Cholesterol, Dietary; Fats, Unsaturated; Female; Humans; Hypercholesterolemia; Hyperlipidemia

1978
Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia.
    Drugs, 1978, Volume: 15, Issue:6

    Topics: Animals; Arteriosclerosis; Clofibrate; Dogs; Humans; Hypercholesterolemia; Hyperlipidemias; Kinetics

1978
[Therapeutic orientation in the hyperlipidemias].
    Arquivos brasileiros de cardiologia, 1979, Volume: 33, Issue:3

    Topics: Cholestyramine Resin; Dextrothyroxine; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic

1979
Cholesterol-lowering drugs as cardioprotective agents.
    The American journal of cardiology, 1992, Dec-21, Volume: 70, Issue:21

    Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA

1992
Management of hyperlipidemia of kidney disease.
    Kidney international, 1990, Volume: 37, Issue:3

    Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolem

1990
Drug therapy in dyslipidemia.
    Scandinavian journal of clinical and laboratory investigation. Supplementum, 1990, Volume: 199

    Topics: Anticholesteremic Agents; Bile Acids and Salts; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA

1990
[The value of chemotherapeutic intervention on primary hyperlipidemias in the prevention of coronary arteriosclerosis].
    Arquivos brasileiros de cardiologia, 1988, Volume: 51, Issue:1

    Topics: Adult; Cholesterol; Clinical Trials as Topic; Colestipol; Coronary Artery Disease; Humans; Hyperlipi

1988
Reducing cardiac deaths with hypolipidemic drugs.
    Postgraduate medicine, 1987, Nov-01, Volume: 82, Issue:6

    Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfi

1987
Contemporary recommendations for evaluating and treating hyperlipidemia.
    Clinical pharmacy, 1986, Volume: 5, Issue:2

    Topics: Clofibrate; Dextrothyroxine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lip

1986
The diagnosis and management of hyperlipidemia.
    Disease-a-month : DM, 1986, Volume: 32, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr

1986
Hypolipidemic drugs.
    Advances in experimental medicine and biology, 1973, Volume: 38

    Topics: Aminosalicylic Acids; Androgens; Bile Acids and Salts; Butyrates; Cellulose; Cholestyramine Resin; C

1973

Trials

19 trials available for probucol and Hyperlipemia

ArticleYear
Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).
    Journal of atherosclerosis and thrombosis, 2021, Feb-01, Volume: 28, Issue:2

    Topics: Aged; Anticholesteremic Agents; Antioxidants; Biological Transport; Cardiovascular Diseases; Carotid

2021
Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study.
    Journal of atherosclerosis and thrombosis, 2021, Feb-01, Volume: 28, Issue:2

    Topics: Anticholesteremic Agents; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Cilost

2021
Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy.
    Renal failure, 2010, Volume: 32, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Hu

2010
Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes.
    Atherosclerosis, 2004, Volume: 174, Issue:2

    Topics: Aged; Analysis of Variance; Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Sele

2004
[Effect of probucol on low-density lipoproteins in patients resistant to diet therapy].
    Arquivos brasileiros de cardiologia, 1982, Volume: 38, Issue:6

    Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hyperlipidemias; Lipopro

1982
Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients.
    La Clinica terapeutica, 1994, Volume: 145, Issue:9

    Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failu

1994
The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans.
    European journal of clinical investigation, 1994, Volume: 24, Issue:11

    Topics: Adult; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combinatio

1994
[Effect of probucol on cardiac electrophysiology in anginal patients with hyperlipidemia and diabetes mellitus type II].
    Terapevticheskii arkhiv, 2000, Volume: 72, Issue:8

    Topics: Aged; Angina Pectoris; Anticholesteremic Agents; Biomarkers; Blood Glucose; Body Mass Index; Cardiac

2000
Probucol (Lorelco) in treatment of hyperlipemia.
    JAMA, 1977, Dec-05, Volume: 238, Issue:23

    Topics: Cholesterol; Clinical Trials as Topic; Humans; Hypercholesterolemia; Hyperlipidemias; Lipoproteins,

1977
Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia.
    Archives of internal medicine, 1977, Volume: 137, Issue:10

    Topics: Adult; Cholesterol; Clinical Trials as Topic; Depression, Chemical; Drug Evaluation; Female; Humans;

1977
Effect of probucol in hyperlipidemic patients during two years of administration.
    American heart journal, 1978, Volume: 96, Issue:2

    Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Female; Humans; Hypercholesterolemia; Hyperlipid

1978
Cholesterol-lowering drugs as cardioprotective agents.
    The American journal of cardiology, 1992, Dec-21, Volume: 70, Issue:21

    Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA

1992
Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients.
    Kidney international. Supplement, 1991, Volume: 31

    Topics: Cholestyramine Resin; Colestipol; Food, Formulated; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Lo

1991
Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with alpha-tocopheryl nicotinate.
    Atherosclerosis, 1990, Volume: 84, Issue:2-3

    Topics: Adult; Aged; Apolipoprotein C-II; Apolipoproteins C; Cholesterol; Cholesterol, HDL; Female; Humans;

1990
A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV.
    The American journal of cardiology, 1990, Sep-18, Volume: 66, Issue:8

    Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Evaluation; F

1990
Comparative study of bezafibrate and probucol in hyperlipidaemia.
    Current medical research and opinion, 1989, Volume: 11, Issue:8

    Topics: Adult; Aged; Bezafibrate; Clinical Trials as Topic; Dietary Fats; Female; Humans; Hyperlipidemias; M

1989
Long-term use of probucol in the multifactorial primary prevention of vascular disease.
    The American journal of cardiology, 1986, Jun-27, Volume: 57, Issue:16

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Cerebrovascular Disorders; Cholesterol, HDL; C

1986
[The value of chemotherapeutic intervention on primary hyperlipidemias in the prevention of coronary arteriosclerosis].
    Arquivos brasileiros de cardiologia, 1988, Volume: 51, Issue:1

    Topics: Adult; Cholesterol; Clinical Trials as Topic; Colestipol; Coronary Artery Disease; Humans; Hyperlipi

1988
The additive effect of probucol on diet in hyperlipidemia.
    Clinical pharmacology and therapeutics, 1974, Volume: 16, Issue:1

    Topics: Adult; Aged; Anticholesteremic Agents; Body Weight; Cholesterol; Clinical Trials as Topic; Diet Ther

1974

Other Studies

76 other studies available for probucol and Hyperlipemia

ArticleYear
Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents.
    Journal of medicinal chemistry, 2011, Aug-11, Volume: 54, Issue:15

    Topics: Animals; Antioxidants; Atherosclerosis; Benzoxazines; Cholesterol, LDL; Farnesyl-Diphosphate Farnesy

2011
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
    Journal of medicinal chemistry, 2013, Apr-25, Volume: 56, Issue:8

    Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mel

2013
New Horizons for Probucol, an Old, Mysterious Drug.
    Journal of atherosclerosis and thrombosis, 2021, Feb-01, Volume: 28, Issue:2

    Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Tria

2021
Study on the Mechanism of Probucol Nanosuspension on Hyperlipidemic Pancreatitis and Regulation of Blood Lipid Function.
    Journal of nanoscience and nanotechnology, 2021, 02-01, Volume: 21, Issue:2

    Topics: Acute Disease; Humans; Hyperlipidemias; Lipids; Pancreatitis; Probucol

2021
Oral absorption enhancement of probucol by PEGylated G5 PAMAM dendrimer modified nanoliposomes.
    Molecular pharmaceutics, 2015, Mar-02, Volume: 12, Issue:3

    Topics: Administration, Oral; Animals; Anticholesteremic Agents; Caco-2 Cells; Cholesterol; Dendrimers; Drug

2015
The Heart Protection Effect of Alcalase Potato Protein Hydrolysate Is through IGF1R-PI3K-Akt Compensatory Reactivation in Aging Rats on High Fat Diets.
    International journal of molecular sciences, 2015, May-05, Volume: 16, Issue:5

    Topics: Aging; Animals; Anticholesteremic Agents; Apoptosis; Cardiotonic Agents; Cholesterol; Diet, High-Fat

2015
Probucol inhibits LPS-induced microglia activation and ameliorates brain ischemic injury in normal and hyperlipidemic mice.
    Acta pharmacologica Sinica, 2016, Volume: 37, Issue:8

    Topics: Animals; Apolipoproteins E; Brain Ischemia; Diet, High-Fat; Dinoprostone; Dose-Response Relationship

2016
Effects of probucol in hyperlipidemic rabbit liver: a preliminary ultrastructural study.
    Okajimas folia anatomica Japonica, 2002, Volume: 79, Issue:2-3

    Topics: Animals; Anticholesteremic Agents; Endoplasmic Reticulum; Female; Hyperlipidemias; Liver; Male; Micr

2002
The effect of probucol on atherosclerosis in streptozotocin-induced diabetic-hyperlipidemic APA hamsters in different stages of atherosclerosis.
    Experimental animals, 2002, Volume: 51, Issue:5

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Aorta; Arteriosclerosis; Cholesterol; Cricetinae; D

2002
Anthocyanins increase low-density lipoprotein and plasma cholesterol and do not reduce atherosclerosis in Watanabe Heritable Hyperlipidemic rabbits.
    Molecular nutrition & food research, 2005, Volume: 49, Issue:4

    Topics: Animals; Anthocyanins; Aorta; Arteriosclerosis; Beverages; Cholesterol; Cholesterol, VLDL; Diet; Ery

2005
Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome.
    Canadian journal of physiology and pharmacology, 2005, Volume: 83, Issue:5

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Atherosclerosis; Catalase; Dietary

2005
Reduction of oxidative stress and apoptosis in hyperlipidemic rabbits by ellagic acid.
    The Journal of nutritional biochemistry, 2005, Volume: 16, Issue:11

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Apopt

2005
Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases.
    Postgraduate medicine, 1983, Volume: 73, Issue:4

    Topics: Adult; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil

1983
Hyperlipidemia: reducing the chances of cardiovascular disease.
    Geriatrics, 1984, Volume: 39, Issue:7

    Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemia

1984
Pharmacologic therapy for the hyperlipidemic patient.
    The American journal of medicine, 1983, May-23, Volume: 74, Issue:5A

    Topics: Bile Acids and Salts; Clofibrate; Dextrothyroxine; Humans; Hyperlipidemias; Hypolipidemic Agents; Ni

1983
Effects of probucol on lipoprotein protein kinetics.
    Artery, 1982, Volume: 10, Issue:2

    Topics: Apolipoproteins; Bile Acids and Salts; Cholesterol; Humans; Hyperlipidemias; Kinetics; Lipoproteins;

1982
One year experience with probucol, a new hypocholesterolaemic agent.
    Singapore medical journal, 1982, Volume: 23, Issue:4

    Topics: Adult; Cholesterol; Female; Humans; Hyperlipidemias; Male; Middle Aged; Phenols; Probucol; Triglycer

1982
[Free and esterified cholesterol of the skin in atherogenic hyperlipidemias].
    Paroi arterielle, 1981, Volume: 7, Issue:2

    Topics: Aged; Cholesterol; Cholesterol Esters; Female; Humans; Hyperlipidemias; Male; Middle Aged; Probucol;

1981
[Evaluation of the effect of probucol on blood lipids].
    Arquivos brasileiros de cardiologia, 1981, Volume: 36, Issue:2

    Topics: Adult; Aged; Cholesterol; Female; Humans; Hyperlipidemias; Male; Middle Aged; Phenols; Probucol; Tri

1981
Drug treatment of hyperlipidemia.
    American heart journal, 1980, Volume: 100, Issue:4

    Topics: Adolescent; Adult; Child; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Humans; Hyperli

1980
[Probuscol (Lurselle)].
    La Nouvelle presse medicale, 1980, Oct-30, Volume: 9, Issue:40

    Topics: Animals; Humans; Hyperlipidemias; Phenols; Probucol

1980
[Hypolipidaemic agents (author's transl)].
    La Nouvelle presse medicale, 1980, Oct-30, Volume: 9, Issue:40

    Topics: Animals; Chemical Phenomena; Chemistry; Cholesterol; Cholestyramine Resin; Clofibrate; Humans; Hyper

1980
Effect of a lipid-lowering agent or a high-cholesterol diet on focal glomerulosclerosis in hyperlipidemic rats.
    Laboratory animal science, 1995, Volume: 45, Issue:1

    Topics: Animals; Body Weight; Cholesterol; Cholesterol, Dietary; Glomerulosclerosis, Focal Segmental; Hyperl

1995
Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
    Arteriosclerosis and thrombosis : a journal of vascular biology, 1994, Volume: 14, Issue:8

    Topics: Animals; Aorta; Arteriosclerosis; Dose-Response Relationship, Drug; Hyperlipidemias; Lipid Peroxides

1994
[The effect of long-term probucol intake on the lipoprotein cholesterol content and glutathione peroxidase activity in the blood of patients with coronary arteriosclerosis and hyperlipidemia].
    Kardiologiia, 1993, Volume: 33, Issue:9

    Topics: Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Coronary Artery Disease; Drug Evaluation; Femal

1993
Indications for the presence of circulating peroxidized low density lipoproteins in WHHL rabbits treated with antioxidants.
    Atherosclerosis, 1993, Volume: 102, Issue:1

    Topics: Animals; Antioxidants; Apolipoprotein B-100; Apolipoproteins B; Hyperlipidemias; Lipid Peroxidation;

1993
Positive correlation between probucol in low density lipoprotein and LDL-lowering.
    European journal of clinical pharmacology, 1993, Volume: 45, Issue:4

    Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Lipoprotein

1993
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.
    Postgraduate medical journal, 1993, Volume: 69, Issue:811

    Topics: Cholesterol, Dietary; Coronary Disease; Diet; Fatty Acids, Omega-3; Female; Humans; Hyperlipidemias;

1993
Protective aspects for atherogenesis and lipid abnormalities in continuous ambulatory peritoneal dialysis patients.
    Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 1993, Volume: 13 Suppl 2

    Topics: Aged; Aged, 80 and over; Arteriosclerosis; Creatinine; Female; Glutathione Peroxidase; Humans; Hyper

1993
Probucol reduces hepatic cholesterol secretion in hyperlipidemic Yoshida rats.
    Atherosclerosis, 1996, Jan-26, Volume: 119, Issue:2

    Topics: Animals; Anticholesteremic Agents; Bile; Body Weight; Cholesterol; Cholesterol Esters; Cholesterol,

1996
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
    Chest, 1997, Volume: 112, Issue:4

    Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem

1997
Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits.
    Arteriosclerosis, thrombosis, and vascular biology, 1997, Volume: 17, Issue:11

    Topics: Administration, Oral; Animals; Antioxidants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Cor

1997
[The antioxidant probucol as a regulator of the intensity of free-radical lipid peroxidation processes in the blood of patients with coronary atherosclerosis].
    Terapevticheskii arkhiv, 1997, Volume: 69, Issue:9

    Topics: Antioxidants; Chronic Disease; Coronary Artery Disease; Drug Evaluation; Female; Free Radicals; Glut

1997
The effect of probucol on intimal thickening of autologous vein grafts in hyperlipidemic rabbit.
    Cardiovascular surgery (London, England), 1997, Volume: 5, Issue:5

    Topics: Animals; Anticholesteremic Agents; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Fe

1997
Probucol treatment attenuates the aortic atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
    Atherosclerosis, 1998, Volume: 137, Issue:1

    Topics: Actins; Animals; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Arter

1998
Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet.
    Virchows Archiv : an international journal of pathology, 1998, Volume: 432, Issue:6

    Topics: Animals; Aorta; Cholesterol; Cholesterol, Dietary; Coronary Artery Disease; Drug Therapy, Combinatio

1998
Lipid lowering therapy in the treatment of lower limb atherosclerosis.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 1998, Volume: 16, Issue:1

    Topics: Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Data Collection; Databases, Bi

1998
Probucol selectively increases oxidation of atherogenic lipoproteins in cholesterol-fed mice and in Watanabe heritable hyperlipidemic rabbits.
    Atherosclerosis, 1999, Volume: 142, Issue:1

    Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Hyperlipidem

1999
Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study.
    Pediatric nephrology (Berlin, Germany), 1999, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Child, Preschool; Electrocardiography; Glomerula

1999
Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits.
    The Journal of clinical investigation, 1999, Volume: 104, Issue:2

    Topics: Animals; Aorta; Arteriosclerosis; Hyperlipidemias; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Ma

1999
Noninvasive 3-D ultrasound of atherosclerotic plaques in the Watanabe rabbit.
    Ultrasound in medicine & biology, 1999, Volume: 25, Issue:6

    Topics: Algorithms; Animals; Anticholesteremic Agents; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; F

1999
Lysophosphatidylcholine molecular species in low density lipoprotein and high density lipoprotein in alloxan-induced diabetic rats: effect of probucol.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 1999, Volume: 107, Issue:6

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Hyp

1999
The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters.
    Atherosclerosis, 2000, Volume: 149, Issue:2

    Topics: Animals; Animals, Newborn; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Cells, Cultured

2000
Syntheses and biological evaluation of 3-substituted amino-1-aryl-6-hydroxy-hex-2-ene-1-ones as antioxidant and hypolipidemic agents.
    Bioorganic & medicinal chemistry, 2000, Volume: 8, Issue:8

    Topics: Alkenes; Animals; Antioxidants; Cholesterol; Cholesterol, LDL; Commiphora; Copper; Ethylamines; Hype

2000
The effect of pharmacological doses of different antioxidants on oxidation parameters and atherogenesis in hyperlipidaemic rabbits.
    Atherosclerosis, 2001, Feb-01, Volume: 154, Issue:2

    Topics: Administration, Oral; Animals; Anticholesteremic Agents; Antidotes; Antioxidants; Aorta; Arterioscle

2001
[Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome].
    Nihon Jinzo Gakkai shi, 2001, Volume: 43, Issue:7

    Topics: Adult; Aged; Anticholesteremic Agents; Cyclosporine; Drug Interactions; Drug Therapy, Combination; F

2001
Hypolipidemic drugs.
    American family physician, 1978, Volume: 17, Issue:2

    Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Humans; Hyperlipidemias; Lipoproteins

1978
Treatment of hyperlipoproteinemias with neomycin, probucol and tibric acid.
    Advances in experimental medicine and biology, 1977, Volume: 82

    Topics: Cholesterol; Feces; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Neomycin; Pheno

1977
[Treatment of hyperlipidemia].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1992, Nov-10, Volume: 81, Issue:11

    Topics: Blood Component Removal; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Dieta

1992
Probucol reduces plasma lipid peroxides in man.
    Atherosclerosis, 1992, Volume: 97, Issue:1

    Topics: Adult; Cholesterol; Humans; Hyperlipidemias; Lipid Peroxides; Male; Middle Aged; Probucol; Vitamin E

1992
[Clinical study of lipid metabolism disorders (discussion)].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1992, Nov-10, Volume: 81, Issue:11

    Topics: Arteriosclerosis; Cholestyramine Resin; Diet; Humans; Hyperlipidemias; Lipid Metabolism; Lovastatin;

1992
Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis.
    Nephron, 1992, Volume: 60, Issue:4

    Topics: Animals; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Male; Nephrotic Syndrome; Probucol; P

1992
Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit--long-term antiatherogenic effect and effects on established plaques.
    Atherosclerosis, 1992, Volume: 92, Issue:2-3

    Topics: Animals; Aorta; Arteriosclerosis; Cholesterol; Female; Hyperlipidemias; Lipids; Male; Probucol; Rabb

1992
Post-marketing surveillance of probucol (Sinlestal) in Japan.
    Artery, 1992, Volume: 19, Issue:3

    Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Electrocardiography; Female; Humans; Hyperlipidemias; Hy

1992
[Hyperlipidemia and drug treatment].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49 Suppl

    Topics: Arteriosclerosis; Carnitine; Cholestyramine Resin; Glomerulonephritis; Humans; Hyperlipidemias; Kidn

1991
Some questions concerning a small, more electronegative LDL circulating in human plasma.
    Atherosclerosis, 1991, Volume: 91, Issue:1-2

    Topics: Animals; Arteriosclerosis; Artifacts; Chromatography, High Pressure Liquid; Chromatography, Ion Exch

1991
Some questions concerning a small, more electronegative LDL circulating in human plasma.
    Atherosclerosis, 1991, Volume: 91, Issue:1-2

    Topics: Animals; Arteriosclerosis; Artifacts; Chromatography, High Pressure Liquid; Chromatography, Ion Exch

1991
Some questions concerning a small, more electronegative LDL circulating in human plasma.
    Atherosclerosis, 1991, Volume: 91, Issue:1-2

    Topics: Animals; Arteriosclerosis; Artifacts; Chromatography, High Pressure Liquid; Chromatography, Ion Exch

1991
Some questions concerning a small, more electronegative LDL circulating in human plasma.
    Atherosclerosis, 1991, Volume: 91, Issue:1-2

    Topics: Animals; Arteriosclerosis; Artifacts; Chromatography, High Pressure Liquid; Chromatography, Ion Exch

1991
The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
    Nephron, 1991, Volume: 58, Issue:1

    Topics: Animals; Hyperlipidemias; Hyperlipoproteinemias; Kidney; Male; Nephrotic Syndrome; Organ Size; Probu

1991
The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits.
    British journal of pharmacology, 1991, Volume: 103, Issue:1

    Topics: Animals; Arteriosclerosis; Cholesterol; Hyperlipidemias; Lipids; Lipoproteins, LDL; Oxidation-Reduct

1991
Antiatherosclerotic effect of probucol in WHHL rabbits: are there plasma parameters to evaluate this effect?
    European journal of clinical pharmacology, 1991, Volume: 40 Suppl 1

    Topics: Animals; Antioxidants; Arteriosclerosis; Female; Hyperlipidemias; Lipid Peroxidation; Male; Probucol

1991
Mechanisms of low density lipoprotein lowering by hypolipidemic agents.
    Annals of medicine, 1991, Volume: 23, Issue:2

    Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Estrogens; Female; Glycoproteins; Humans; Hyd

1991
Treatment of hyperlipidemia with probucol reduces proteinuria in puromycin aminonucleoside-induced nephrotic rats.
    Nephron, 1990, Volume: 54, Issue:4

    Topics: Animals; Hyperlipidemias; Male; Nephrotic Syndrome; Phenols; Probucol; Proteinuria; Puromycin Aminon

1990
Hypercoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis. Effect of probucol on coagulation.
    Thrombosis and haemostasis, 1989, Feb-28, Volume: 61, Issue:1

    Topics: Aging; Animals; Arteriosclerosis; Blood Coagulation Factors; Disease Models, Animal; Hyperlipidemias

1989
Prevention of atherosclerotic progression in Watanabe rabbits by probucol.
    The American journal of cardiology, 1988, Jul-25, Volume: 62, Issue:3

    Topics: Animals; Arteriosclerosis; Cells, Cultured; Drug Evaluation, Preclinical; Female; Foam Cells; Hyperl

1988
In vivo inhibition of foam cell development by probucol in Watanabe rabbits.
    The American journal of cardiology, 1988, Jul-25, Volume: 62, Issue:3

    Topics: Animals; Arteriosclerosis; Depression, Chemical; Drug Evaluation, Preclinical; Foam Cells; Hyperlipi

1988
Medical management of hyperlipidemia and the role of probucol.
    The American journal of cardiology, 1986, Jun-27, Volume: 57, Issue:16

    Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem

1986
Current pharmacologic treatment of elevated serum cholesterol.
    Circulation, 1987, Volume: 76, Issue:3

    Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co

1987
Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in
    Proceedings of the National Academy of Sciences of the United States of America, 1987, Volume: 84, Issue:21

    Topics: Animals; Antioxidants; Aorta; Arteriosclerosis; Cholesterol; Hyperlipidemias; Lipoproteins, LDL; Lov

1987
Adverse effects of the treatment for hyperlipidemia.
    Cardiology clinics, 1986, Volume: 4, Issue:1

    Topics: Anion Exchange Resins; Anticholesteremic Agents; Bibliographies as Topic; Clofibrate; Diet; Drug The

1986
Drug therapy for lipid disorders. Selecting appropriate lipid-lowering agents.
    Postgraduate medicine, 1987, Volume: 82, Issue:1

    Topics: Anticholesteremic Agents; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyper

1987
Effect of probucol on hyperlipidemia in patients with nephrotic syndrome.
    Nephron, 1987, Volume: 47, Issue:4

    Topics: Adult; Cholesterol; Female; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Male; Mid

1987
A symposium: New developments in the treatment of hypercholesterolemia--probucol. December 7, 1985, New York, New York.
    The American journal of cardiology, 1986, Jun-27, Volume: 57, Issue:16

    Topics: Humans; Hypercholesterolemia; Hyperlipidemias; Phenols; Probucol

1986
Probucol, blood lipids and the ECG QTc interval.
    Irish medical journal, 1986, Volume: 79, Issue:2

    Topics: Adult; Aged; Electrocardiography; Female; Humans; Hyperlipidemias; Lipids; Lipoproteins; Male; Middl

1986
[Probucol in the treatment of hyperlipidemias].
    Arquivos brasileiros de cardiologia, 1986, Volume: 46, Issue:2

    Topics: Animals; Cholesterol; Humans; Hyperlipidemias; Phenols; Probucol; Rabbits; Rats; Triglycerides

1986
Plasma carnitine and lipid-lowering drugs.
    Atherosclerosis, 1985, Volume: 55, Issue:3

    Topics: Carnitine; Cholesterol, HDL; Clofibrate; Female; Humans; Hyperlipidemia, Familial Combined; Hyperlip

1985
Effect of probucol on triton induced hyperlipidemias in CFY rats.
    Artery, 1985, Volume: 13, Issue:2

    Topics: Animals; Cholesterol; Clofibrate; Hyperlipidemias; Hypolipidemic Agents; Male; Phenols; Polyethylene

1985
[New derivatives of clofibrate and probucol. Preliminary study of their hypolipemic activity].
    Il Farmaco; edizione scientifica, 1985, Volume: 40, Issue:11

    Topics: Animals; Chemical Phenomena; Chemistry; Clofibrate; Hyperlipidemias; Hypolipidemic Agents; Male; Mic

1985